• This collaboration will fully utilize Medigene's leading advantages in T cell receptor (TCR) generation and characterization research, as well as WuXi Biologics' unique CD3 antibody, T cell engager (TCE) technology platform and patented bispecific antibody technology platform WuXiBody.
• This collaboration is for a period of three years and may involve multiple TCR projects.

SHANGHAI, China and MUNICH, Germany, Aug. 8, 2024 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced today that it has entered into a three-year strategic research service collaboration with Medigene AG (Medigene, FSE: MDG1, Prime Standard), a TCR-based immuno-oncology company. The strategic collaboration will cover multiple targets and is aimed to design and research T cell receptor-engineered T cell engager (TCR-TCE) therapies for the treatment of refractory tumors. This collaboration will combine Medigene's TCR generation and characterization capabilities, which possess sensitivity, specificity and safety (3S), with WuXi Biologics' unique CD3 antibody, industry-leading TCE technology platform and patented bispecific antibody technology platform WuXiBody, to accelerate the research process for refractory tumor therapies.

Dr. Chris Chen, CEO of WuXi Biologics, commented, "Medigene is a leading enterprise in the TCR generation and characterization research field, and we are pleased to partner with them. This collaboration further highlights the advantages of our CRDMO business model in research services, and demonstrates our commitment to helping global partners accelerate the development of innovative products with our leading technology and reliable services. We believe that this collaboration will bear fruit and bring good news to cancer patients around the world."

Mr. Selwyn Ho, CEO of Medigene, said, "We are delighted to enter into this research collaboration with WuXi Biologics. WuXi Biologics' unique CD3 antibody has been widely validated and, combined with its leading WuXiBody and TCE platforms, it can support our application of TCRs in new molecular forms, including TCR-engineered T cell engagers, which are expected to achieve higher clinical value for patients compared to TCR-T therapy. Medigene's strength in developing potential best-in-class 3S TCRs for TCR-T cell therapy is well recognized, and we believe that we can further expand this ability to non-cellular therapy, continuously provide better treatment options for patients, and create long-term value for shareholders. "

WuXiBody is WuXi Biologics' proprietary bispecific antibody technology platform. The platform overcomes many technological bottlenecks in most bispecific antibody platforms, possesses advantages such as high expression levels, high stability, good solubility and easy purification, and can save 6 to 18 months of R&D time and significantly reduce bispecific antibody production costs for each project, achieving more cost-effective and environmentally friendly drug development. The WuXiBody platform can almost use all antibody sequences to construct bispecific antibodies, and is expected to reduce immunogenicity risk and prolong in vivo half-life. The WuXiBody platform also has unique flexibility and can construct various valencies (such as bivalent, trivalent or tetravalent bispecific antibodies) to meet the biological characteristics required by different projects.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global open-access biologics technology platform offering end-to-end solutions to empower and accelerate biologics discovery, development, and manufacturing. The company's services are designed to help its partners achieve their goals at all stages of the biologics life cycle, from concept to commercial manufacturing. WuXi Biologics' innovative platforms and solution-focused services are designed to help customers bring innovative biologics products to market faster and more efficiently, ultimately benefiting patients worldwide.

WuXi Biologics has over 12000 employees in China, the United States, Ireland, Germany and Singapore. With its professional service team and advanced technology and insights, the company provides efficient and cost-effective solutions for its clients. As of the end of December 2023, WuXi Biologics has helped clients develop and produce a total of 698 projects, including 24 commercial production projects.

WuXi Biologics regards environmental, social and governance (ESG) as an important part of the business development and corporate spirit. The company is committed to becoming a global ESG leader in the field of biologics CRDMO, such as leading the industry development with greener and more environmentally friendly new-generation biologics technology and energy. The company has established an ESG committee led by the CEO to implement the ESG strategy comprehensively and practice the commitment to sustainable development. For more information, please visit:

About Medigene AG

Medigene AG (FSE: MDG1) is a biotechnology company that focuses on T-cell receptor (TCR) cancer immunotherapy. The company's end-to-end development platform can generate optimized TCRs that have sensitivity, specificity and safety, and these TCRs have unique differentiated characteristics that are suitable for various drug molecules, including TCR-engineered T-cell therapy (TCR-T), TCR-mediated T-cell engager (TCE) therapy, and TCR NK cell therapy, and are widely used in the company's own development pipeline and cooperation drug molecule research and development.

Medigene's core drug molecule under development, MDG1015, is a TCR-T therapy that is expected to treat multiple solid tumors and has the best potential among similar products. The company's self-owned end-to-end platform technology can enhance the ability of T cells to overcome the immunosuppressive effects of tumor microenvironments (TME), ensure the safety, efficacy and persistence of T cell therapy. MDG1015 is expected to be submitted for IND declaration in the third quarter of 2024 and for CTA declaration in the fourth quarter of 2024. For more information, please visit